Introduction and dimension of the problem
Nonalcoholic fatty liver disease (NAFLD) is the most common hepatic alteration in the Western world, due to its well-established association with the metabolic syndrome, the prevalence of which is increasing in both affluent and developing countries. The more severe form of NAFLD, nonalcoholic steatohepatitis (NASH), is characterized by inflammatory infiltration and hepatocellular damage, with or without fibrosis. While simple (or bland ) steatosis is considered a relatively benign condition due to the extremely low likelihood to ' ' progress to cirrhosis 1, 2 , NASH is associated with the potential to progress to the entire clinical picture of advanced liver disease.
[ ] Indeed, fat accumulation in the liver generates inflammatory signals and reactive oxygen species that can amplify liver injury and stimulates fibrosis. This is similar to the picture observed in different etiologies of chronic liver injury, such as chronic HCV or HBV infection, where the spectrum of alterations may range from a near normal liver to severe hepatitis and cirrhosis. The development of NASH is the result of a complex interaction between the environment, represented in the case of NAFLD by a sedentary lifestyle and excessive intake of calories, and individual predisposition, that affects both the development of excess adiposity and its consequences.
In Europe, NAFLD is the underlying cause of damage in 40 60 patients with mild fibrosis 3 , and in the USA, where one third of
the population is overweight, it is estimated that 9 million patients have different degrees of NASH 4 . The actual role of NASH as a [ ] primary cause of advanced liver disease is not well known. Some reports suggest that NASH is the underlying cause of cirrhosis in 1 3 -% of patients undergoing liver transplantation, but compared to other chronic liver diseases, NASH-related cirrhosis is less likely to undergo transplantation, and this may underestimate the relevance of this disease as a cause of end-stage liver disease. Nonetheless, NASH is considered the principal cause of most cases of cryptogenic cirrhosis, and therefore the significance of NAFLD as a cause of end-stage liver disease is probably not negligible 5 . More important, due to the worldwide epidemics in obesity, the prevalence of end-stage liver [ ] disease among NAFLD patients is expected to rise in the future.
Like for any other chronic liver disease, appearance and progression of fibrosis is a critical event in the course of NASH, although fibrosis does not represent a prerequisite for a diagnosis of NASH. Besides the role of NASH as a factor potentially leading to cirrhosis, 2 24 decompensation, and hepatocellular carcinoma 6 , several studies have highlighted the existence of an increased cardiovascular risk in [ ] these patients 1 . These data clearly indicate that treatment of NASH is an unmet need of outstanding relevance in Hepatology and [ ] Internal Medicine. This review will summarize the available evidence defining critical aspects of the pathophysiology of NASH. As no established treatment exists for this condition, discussion will be focused on the potential therapeutic targets that have been highlighted by experimental studies, and by recent advances in the field of adipose tissue biology and inflammation. In addition, reference will be made to clinical studies where approaches suggested by experimental investigation have been translated to the clinical practice. However, a detailed analysis of published clinical trials for the treatment of NASH is outside the scopes of this paper, and the reader may refer to several recent reviews 7 9 .
[ -]
Significance of NASH progression
Although the natural history of NAFLD is not well known, most studies suggest that the existence of NASH is a prerequisite to develop progressive fibrosis. On the other hand, the appearance and development of fibrosis represents a critical factor for the eventual progression to cirrhosis and end-stage liver disease. Like for other chronic liver diseases, identifying the patients that are more likely to progress is a clinical challenge. In the field of NASH, not only it is relevant to know the stage of fibrosis in the presence of established NASH, but it also often necessary to differentiate simple, non-evolutive steatosis from steatohepatitis. A number of clinical factors have been demonstrated to provide some prediction of the likelihood to observe advanced fibrosis or cirrhosis in a given patient. Age >45 years has been shown to predict fibrosis and cirrhosis in different studies 10, 11 . In contrast, race and female gender have been identified as [ ] predictive factors only in a minority of studies 11 . Components of the metabolic syndrome are also associated with disease progression, [ ] and the majority of patients presenting with NASH have metabolic abnormalities, including type 2 diabetes, obesity, dyslipidemia, and hypertension. In particular, diabetes, obesity, and hypertension have been independently associated with advanced disease 10 14 . Finally, [ -] more advanced fibrosis parallels the number of components of the metabolic syndrome present in the patients 15 .
[ ]
Genetic factors
Recent studies have demonstrated that polymorphisms of a number of candidate genes, including those encoding for immunoregulatory proteins, proinflammatory cytokines and fibrogenic factors, could influence the appearance of NASH and the eventual development of liver fibrosis in patients with NAFLD 16 . Genetic variations can explain susceptibility to develop NASH in patients with [ ] obesity and/or diabetes. Moreover, it has been hypothesized that genetic factors influence fibrosis progression. The role of HFE C282Y
heterozygosity and iron accumulation are unclear, since studies have yielded contradictory results 17 . Combination of polymorphisms in [ ] profibrotic genes such as angiotensinogen and TGF 1 are associated with advanced fibrosis, and polymorphisms in genes encoding for . Finally, a recent report using a genome-wide association study identified several genes that regulate the susceptibility to develop NASH, including farnesyl diphosphate farnesyl transferase 1 19 , although other studies have not confirmed these findings. The results of these [ ] studies suggest that genetic variations could at least in part explain the broad variability in the natural history of NAFLD among patients with metabolic syndrome.
Fatty liver and insulin resistance: where it all begins?
Steatohepatitis develops only in a fraction of patients with NAFLD, while the majority presents with only simple steatosis, but the ' ' two entities are considered part of the same disease spectrum. While fat accumulation is the common denominator of all forms of NAFLD, from a pathophysiological standpoint NASH develops when the excess lipid accumulation results in hepatic lipotoxicity. Toxic effects on hepatocytes, and possibly other liver cells, provokes injury, which in turn triggers an inflammatory and would healing response that is the ' ' basis for the eventual development of fibrosis. Thus, a critical concept is that increased hepatic fat does not invariably result in hepatocellular damage, and understanding the mechanisms leading to lipotoxicity is of pivotal importance for the comprehension of this field. Anyhow, fat accumulation appears to be a prerequisite for the development of NASH. Therefore, it is also relevant to understand the events that lead to the initial accumulation of fat in the context of the metabolic syndrome.
Fatty liver
Fat accumulates in the liver mainly in the form of triglycerides, although several other lipid species are present. Human and animal studies have shown that accumulation of triglycerides in NAFLD is the result of the expansion of the intrahepatic pool of free fatty acids (FFA). FFA influx is dependent on: a) the amount of FFA released by the adipose tissue due to insulin resistance and excessive lipolysis (see below); b) dietary fat via chylomicron metabolism; c) lipogenesis (Figure 1 ). On the other hand, the liver may dispose of FFA de novo mainly via fatty acid oxidation, both in the mitochondria and at extramitochondrial sites, or through assembly and export of triglycerides with VLDL. Human and animals studies have shown that more than half of the FFA pool is derived from excess adipose tissue lipolysis [ 
.
Importantly, the pathways that lead to FFA disposition are usually activated at a higher level in patients with NAFLD, indicating that ] the critical factor leading to fat accumulation is related to excessive inflow of FFA rather than to limited oxidation. In fact, insulin is no longer capable to suppress VLDL secretion, and this results in atherogenic dyslipidemia, characterized by low HDL and high LDL-cholesterol 21 . A remarkable exception to this view is represented by patients with impairment of VLDL assembly, as occurs in [ ] familial hypobetalipoproteinemia, where high levels of hepatic TG are not associated with insulin resistance or steatohepatitis 22 .
[ ] Although NASH occurs in the context of a fatty liver, it still remains to be established whether steatosis should be considered a per se primary target for the treatment of NASH. Some clinical studies would argue in this direction, as the amount of fat accumulating in the liver is a predictor of the presence of NASH. Nonetheless, experimental studies clearly demonstrate that interference with triglyceride accumulation and effective decrease of steatosis may not only be ineffective in ameliorating steatohepatitis, but could even worsen this condition. Diacylglycerol acyl transferases (DGAT) catalyze the final incorporation of a fatty acid in triglycerides. Inhibition of DGAT2 with antisense oligonucleotides was effective in reducing steatosis but caused more severe inflammation, oxidative stress and fibrosis 23 .
[ ]
In contrast, mice with hepatic overexpression of DGAT2 developed marked hepatic steatosis without liver injury or insulin resistance 24 .
[ ] Nonetheless, the role of DGATs in NASH is more complex. Overexpression of DGAT1 in adipocytes and macrophages resulted in protection from adipose tissue and systemic inflammation, in spite of more severe obesity. On the other hand, DGAT1 knockout was found to be ineffective on steatosis, while it decreased fibrogenesis, increasing the amount of vitamin A stored in hepatic stellate cells (HSC) and inducing a less fibrogenic phenotype 25 .
[ ] These results are of particular relevance, because they indicate that simply reducing the amount of triglycerides stored in the liver is unlikely to be an appealing target for the treatment of NASH. Dissociation between steatosis, insulin resistance and the features of NASH is also shown by data from the hepatic effects of bariatric surgery. While most of the available studies indicate that weight loss induced by this procedure is associated with reduced insulin resistance and an improvement of steatosis, the effects on necro-inflammation and fibrosis are more debatable 26 . Based on these observations, it appears that lipotoxicity that causes hepatocellular damage and [ ] subsequently NASH, should not be considered a synonym of steatosis (Figure 2 ). Moreover, these considerations introduce another unaddressed issue in the field of NASH, i.e. whether steatohepatitis develops in some patients after the appearance of a fatty liver or if the two entities originate as such in the individual patient. Although this uncertainty is difficult to be solved experimentally or with human studies, it is conceptually very important because it would allow the investigators to follow less strictly those patients without signs of inflammation and damage.
Insulin resistance
The degree of insulin resistance or the presence of diabetes are predictors of the existence of NASH or of a more advanced stage of fibrosis, suggesting a role for this disorder in the pathogenesis of steatohepatitis. Schematically, the current view suggests that insulin resistance originates at the level of the expanded and inflamed adipose tissue (see below), eventually involving the skeletal muscle, the pancreas, and the liver 7 . The presence of a fatty liver in turn contributes to the reduced response to insulin and aggravates alterations in [ ] glucose and lipid metabolism. It is well established that insulin resistance is associated with elevated levels of circulating insulin, and in hepatocytes, not all insulin-activated pathways are equally insensitive to the hormone. In fact, the ability of insulin to stimulate lipogenesis is maintained, via activation of the transcription factor sterol regulatory element binding protein-1c 20 . In addition, insulin preserves its [ ] mitogenic effects, that may contribute to promote carcinogenesis 27 .
[ ] Along these lines, the possibility that other liver cells have an altered response to insulin has not been adequately addressed, but there are several experimental data suggest a possible direct role of insulin resistance in the pathogenesis of NASH and fibrosis. In particular, hepatic stellate cells (HSC) express receptors for insulin, insulin-like growth factor-I, and advanced glycation end-products, all of which generate profibrogenic signals, e.g. increasing the expression of type I collagen and connective tissue growth factor (CTGF) 28 . These [ ] In spite of the conceptual basis for the involvement of insulin resistance, the results of experimental studies and clinical trials did not provide definitive evidence indicating that modulation of this disturbance is effective for the treatment of NASH. Metformin, an activator of adenosine monophosphate-regulated kinase (AMPK), ameliorates glucose metabolism, has anti-inflammatory properties, and may interfere with profibrogenic pathways 30 . In spite of these actions, several published trials failed to show a consistent effect on NASH 31
. Thiazolidinediones (TZD) have been extensively evaluated for the treatment of NAFLD and NASH, and different studies in animal ] models and in patients have been published 7 . TZD mainly act activating the transcription factor peroxisome proliferator-activated [ ] receptor (PPAR)-gamma, which in turn targets pathways that may be beneficial in the treatment of NASH. PPAR-gamma activation improves insulin sensitivity in the adipose tissue and in the liver. In addition it induces adipose tissue differentiation towards a triglyceride-storing phenotype, limiting lipolysis. In the liver, TZD have been shown to be anti-inflammatory and anti-fibrogenic, acting on different targets, some of which are independent of PPAR-gamma, including NF-kappaB and AMPK. Specifically, PPAR-gamma has been
shown to reduce Kupffer cell activation and cytokine secretion, and to polarize macrophages towards an anti-inflammatory phenotype 32 .
[ ] PPAR-gamma-deficient mice fed a high-fat diet or administered a methionine-and choline-deficient diet are more sensitive to lipid accumulation or to the development of steatohepatitis 33 . PPAR-gamma is highly expressed in adipocytes, but is present also in different 
Signals from outside the liver
NAFLD is a typical systemic disease, where complex metabolic alterations affect the liver and many other tissues. While the critical step that leads to steatohepatitis is hepatocellular lipotoxic damage secondary to fat accumulation, the pathogenesis of NASH is far more complex and involves both a cross-talk among different resident and infiltrating liver cells, and the contribution of factors depending on extrahepatic systems.
Adipose tissue
Overweight and obesity are a major risk factor for NAFLD, and predict the eventual appearance of diabetes and other metabolic complications. Current knowledge points at the adipose tissue as a critical site for both the development of insulin resistance and the appearance of the changes that ultimately will cause NASH. While the initial site of alterations responsible for the reduction of insulin sensitivity remains debated, peripheral (i.e. adipose tissue) insulin resistance is considered a critical factor for the eventual development of demonstrated that lack of ATGL protects mice from tunicamycin-induced endoplasmic reticulum stress, in part via modification of the fatty acid profile. In mice with liver-specific inactivation of ATGL, severe progressive hepatic steatosis was found, although this was not associated with major metabolic abnormalities 41 . Moreover, while plasma ALT levels were elevated, inflammation and fibrosis were [ ] similar to or lower than those in controls.
The role of different lipases has also been evaluated in the light of the observation that mutations in PNPLA3 (adiponutrin) have an impact on the development of NAFLD and possibly on its progression. PNPLA3 has emerged from several genome-wide association studies as a potent factor predisposing to fatty liver 42 . Eventually, it has been reported that PNPLA3 mutations are also associated with a [ ]
In this scenario, activation of JNK has been associated with increased serine phosphorylation of IRS, reducing the response to insulin [ fibrogenic and inflammatory cells remain sensitive to the actions of this adipokine, contributing to the progression of NASH. Thus, similar to other therapeutic approaches, it is likely that interference with the action of leptin is more promising if targeted to the cells that are more directly involved in inflammation and repair.
. In addition, NF-kappaB activation leads to increased expression of several proinflammatory cytokines and chemokines that amplify

Adiponectin
Adiponectin increases insulin sensitivity and has in general a hepatoprotective and antifibrogenic effect in the liver wound healing while hypoadiponectinemia associated with obesity may be a key factor for Kupffer cell activation and steatohepatitis.
The adiponectin system represents therefore an appealing target for the treatment of NASH and the metabolic syndrome 84 . Some of [ ] the drugs that are currently used, including thiazolidinediones or metformin, exert at least part of their actions modulating the adiponectin system or its intracellular targets, such as AMPK. In addition, adiponectin receptors could be potentially targeted by the use of agonists.
However, the relevance of these findings needs to be further validated in patients with NASH, because hypoadiponectinemia is a characteristic of patients with metabolic syndrome, but correlation to NASH has been inconsistently reported 7 .
Other adipocytokines
Other adipokines could possibly participate in hepatic inflammation and fibrosis. These include resistin, that has been shown to modulate both inflammation and hepatic stellate cell biology 85, 86 , and visfatin, which has been associated with propagation of lipotoxic 
The renin-angiotensin system
Accumulating data indicate that the renin-angiotensin system is a major modulator of insulin resistance and therefore may have a particular relevance in patients with NASH 28 . [ ]
Intestine and the microbiome
In the last few years considerable attention has been directed to a possible direct role of the microbiome in the pathogenesis of NAFLD and NASH, with very intriguing results. Availability of novel sequencing techniques allows a comprehensive and detailed analysis of the microbiome, which has led to the identification of different enterotypes in the general population 92 . Analysis of the role of different
families of intestinal bacteria has been performed in several conditions, including obesity, and it has been proposed that the microbiome 7 24 contributes to the susceptibility to become obese and to gain or lose weight more effectively why on a given dietary regimen 93 . which level(s) the inflammasome is critical, in particular whether defects in the intestine are sufficient to transmit the phenotype.
Moreover, these data should be reconciled with other studies implicating a deleterious effect of inflammasome activation in the pathogenesis of NASH 99, 100 .
Dietary factors
While there is general agreement that a reduction in calorie intake is beneficial for NASH, as part of a complex lifestyle intervention [ 101 , it is uncertain whether changes in the type of nutrients may be an additional approach to be pursued in the treatment of this condition. lipotoxic than mono-or polyunsaturated ones, mainly due to their lower ability to be incorporated in less toxic triglycerides and to higher induction of apoptosis 104 106 .
Monounsaturated fatty acids are part of the Mediterranean diet which has been suggested to be beneficial in the metabolic syndrome [ ]
Inside the liver: local inflammatory and fibrogenic mechanisms
Sustained inflammation in the liver is critical in the progression of NAFLD. Compelling evidences indicates that hepatic macrophages, comprising liver-resident macrophages (Kupffer cells) and monocytes infiltrating the injured liver, as well as specific lymphocyte subsets, play a pivotal role in the initiation and perpetuation of the inflammatory response, with a major deleterious impact on key steps of fatty liver progression to fibrosis. [ ]
Kupffer cell activation affects multiple steps of NAFLD
Pattern recognition receptors (PRR)
Obesity is associated with increased gut permeability, leading to translocation of bacterial products which interact with pattern recognition receptors (PRR). Originally described as a defense mechanism against pathogens (bacteria, viruses and fungal components), TLR are a family of receptors that recognize gut-derived bacterial products such as lipopolysaccharide (LPS), bacterial DNA, peptidoglycan, viral and fungal components originating from gut microbiota, but also denatured host DNA and indirectly free fatty acids [ permeability and composition of gut microbiome in obesity, both in humans and experimental models 167 169 . As a result, Kupffer cells [ -] and other liver cells, in particular stellate cells and hepatocytes are exposed to a high load of gut-derived bacterial products that function as TLR ligands to promote NAFLD progression. Taken together, these data undoubtedly point out the major impact of the NF-B and JNK pathways, in myeloid cells and hepatocytes, κ in insulin resistance and various aspects of NASH. They also further argue for a cross talk between hepatocytes and Kupffer cells in the pathogenesis of NASH. However, they underscore the complex cell specific roles of these signaling pathways in disease progression.
Lymphocytes
In addition to Kupffer cells, NAFLD progression is also governed by alterations in lymphocyte subsets. Indeed, fat-laden Kupffer cells promote recruitment of CD4 , CD8 and B lymphocytes 161 , and cause hyperresponsiveness to chemotactic agents in obese mice 199 .
Moreover, alterations in the Treg/Th17 balance has also been hypothesized. showing that daily cannabis smoking is an independent predictive factor of fibrosis severity and fibrosis stage in patient with chronic hepatitis C 224 .
[ ] These data show that peripheral overactivation of CB1 receptors contributes to the progression of NAFLD, by acting at multiple steps of the disease. However, rimonabant has been withdrawn from the market, given an alarming rate of side effects on the central nervous system. This major drawback could soon be overcome with the emerging availability of CB1 antagonists unable to cross the blood-brain strategies that chronically reduce apoptosis could potentially favor the appearance of hepatocellular carcinoma, the incidence of which has been found to be increased in patients with NAFLD even in the absence of cirrhosis.
ER stress
One of the consequences of lipotoxicity is the activation of the so-called unfolded protein response (UPR) that is characterized by a 
Lipid droplets and autophagy
In hepatocytes, excess fat in form of triglycerides is stored in separate structures known as lipid droplets. [ ] Moreover, the levels of autophagy were increased upon liver injury in mice and in human samples. Loss of autophagic function in mice following injury reduced fibrogenesis and matrix accumulation 241 .
Mitochondria and oxidative stress
Oxidative stress has been traditionally considered one of the second-hits responsible for the progression from steatosis to and other studies have highlighted to potential relevance of nutraceuticals in this field.
' '
Conclusions and perspectives
Steatohepatitis developing in patients with the metabolic syndrome is a relevant clinical problem, and a targeted therapy still an unmet need. While weight loss and physical exercise have provided clear benefits, a pharmacological therapy needs an in-depth knowledge of the pathogenetic aspects that are associated with the appearance of steatohepatitis. This entity appears to be separated by the simple steatosis observed in the majority of patients, and a wealth of information has accumulated in the past 10 years on several aspect of the pathogenesis of NASH. Application of translational research, which combines studies in humans with mechanistic information from preclinical investigation is the challenge for the discovery of new therapeutic targets. The data discussed above demonstrate not only that a wide number of potential therapeutic targets are available (Table 1) , that for many of those a pharmacological targeting is feasible or even already available. Nonetheless, the active elucidation, through controlled clinical trials, of the therapies that could be of benefit for this condition, is still hampered by the need of a liver biopsy to differentiate simple steatosis from true NASH. Thus, the search for a targeted therapy is closely linked to research that aims to identify easy-to-use tests to at least narrow down the population of patients to subject to liver biopsy and to start on a therapeutic trial. The explosion of information on this condition witnessed in the past few years is likely to lead in reasonable time to new and targeted therapies.
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Figure 1
Central role of free fatty acids (FFA) in the pathogenesis of NAFLD In the presence of insulin resistance, the majority of FFA reaching the liver derive from adipose tissue lipolysis. Lipids from the diet or de novo lipogenesis also contribute to expand the FFA pool. In the hepatocyte, FFA may be oxidized at mitochondrial and extramitochondrial sites, or incorporated in triglycerides. These in turn may be accumulated in lipid droplets, leading to steatosis or secreted in the circulation as VLDL, leading to a proatherogenic lipid pattern.
Figure 2
The fate of excess fatty acids is linked to the severity of nonalcoholic fatty liver disease Increased hepatic inflow of fatty acids due to peripheral insulin resistance is associated in some patients with lipotoxic injury, while in other to limited damage. Experimental evidence indicates that accumulation of triglycerides may represent a protective mechanism to limit the toxic action of fatty acids and other lipotoxic products. In the presence of lipotoxicity, steatohepatitis develops possibly leading to end stage liver disease and its complications.
Figure 3
Contribution of the adipose tissue to the development of nonalcoholic steatohepatitis In the lean subject, M2-polarized macrophages and regulatory T cells (Treg) predominate in the vascular stromal fraction. Weight gain leads to expansion of the adipose tissue, resulting in tissue hypoxia and adipocyte apoptosis, leading to secretion of chemotactic cytokines such as CCL2 (MCP-1). CCL2 secretion recruits M1-polarized macrophages that secrete proinflammatory cytokines, contributing to insulin resistance, which increases lipolysis and the delivery of free fatty acids (FFA) to the liver. The expanded and inflamed adipose tissue also causes an imbalance in adipokine secretion, with an increase in leptin and a decrease in adiponectin circulating levels.
Figure 4
Dietary factors influence the development of steatohepatitis Saturated fatty acids, particularly palmitic acid, are highly lipotoxic and may lead to apoptotic cell death. In contrast, n-3 PUFA have a protective effect on steatosis. Free cholesterol targets the mitochondria, and contributes to lipotoxicity and apoptosis. Fructose favors steatosis and contributes to injury, inflammation and fibrogenesis increasing the availability of lipopolysaccharide (LPS), increasing the levels of advanced glycation end-products (AGE), increasing iron and depleting copper.
Figure 5
Pivotal role of activated Kupffer cells in the pathogenesis of nonalcoholic steatohepatitis and fibrogenesis Increased levels of lipoipolysaccaride (LPS) and lipotoxic lipid products lead to activation of Kupffer cells, which release chemotactic factors (e.g. CCL2), and proinflammatory cytokines, and generate oxidative stress-related products including reactive oxygen species (ROS). These factors contribute to hepatocyte injury, which in turn, through danger signals, cause further activation of toll-like receptors (TLRs). In addition, inflammation and damage contribute to hepatic stellate cell activation and fibrosis.
